Forma Therapeutics, Inc.

Aventis Pharmaceuticals Inc.

Alan Collis

Susan Ashwell

Wei Lu

Duncan Walker

Patrick F Kelly

Blythe Thomson

Jeff Davis

Yong Mi Choi-Sledeski

Gregory Bernard Poli

Julian Roy Levell

Mark Czekaj

Roy J Vaz

Lu Wei

Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)

Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).

Inhibiting mutant IDH-1

Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.

Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation

Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)

Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation

The present invention relates to a series of substituted 3-aminopropane phosphinic acid derivatives of formula I: wherein R, R, P, Pand Pare as defined herein. The compounds of this invention are useful in treating a variety of diseases including but not limited to depression, anxiety, certain psychiatric symptoms, cognitive impairment and schizophrenia.

Substituted propane phosphinic acid derivatives

The present invention relates to certain esters of substituted 3-aminopropane phosphinic acid derivatives of formula I: wherein R, Rand Rare as defined herein. The compounds of this invention are useful in treating a variety of diseases including but not limited to depression, anxiety, certain psychiatric symptoms, cognitive impairment and schizophrenia.

Substituted propane phosphinic acid esters

Growing community of inventors

Lexington, MA, United States of America

Alan Collis